Noninvasive estimation of fibrosis progression overtime using the FIB- 4 index in chronic hepatitis C

Journal of Viral Hepatitis

Volumn 20, Issue 1, 2013, Pages 72-76

  Tamaki, N ^a   Kurosaki, M ^a   Tanaka, K ^a   Suzuki, Y ^a   Hoshioka, Y ^a   Kato, T ^a   Yasui, Y ^a   Hosokawa, T ^a   Ueda, K ^a   Tsuchiya, K ^a   Nakanishi, H ^a   Itakura, J ^a   Asahina, Y ^a   Izumi, N ^a  

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

Author keywords

FIB 4; fibrosis; HCV; noninvasive

Indexed keywords

ADULT; ARTICLE; CORRELATION ANALYSIS; DETERIORATION; DISEASE COURSE; FEMALE; FIB 4 INDEX; HEPATITIS C; HUMAN; INCIDENCE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM;

ADULT; AGE FACTORS; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOPSY; COHORT STUDIES; DEMOGRAPHY; DISEASE PROGRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84871005333     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2012.01635.x     Document Type: Article

References (31)

1. Dienstag JL,. The role of liver biopsy in chronic hepatitis C. Hepatology 2002; 5 (Suppl 1): S152-S160.
2. Benvegnu L, Gios M, Boccato S, Alberti A,. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004; 53 (5): 744-749.
3. Serfaty L, Aumaitre H, Chazouilleres O, et al. Determinants of outcome of compensated hepatitis C virus- related cirrhosis. Hepatology 1998; 27 (5): 1435-1440.
4. Gebo KA, Herlong HF, Torbenson MS, et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology 2002; 5 (Suppl 1): S161-S172.
5. Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K,. The role of liver biopsy in chronic hepatitis C. Hepatology 2001; 33 (1): 196-200.
6. Bravo AA, Sheth SG, Chopra S,. Liver biopsy. N Engl J Med 2001; 344 (7): 495-500.
7. Bedossa P, Dargere D, Paradis V,. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38 (6): 1449-1457.
8. Colloredo G, Guido M, Sonzogni A, Leandro G,. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39 (2): 239-244.
9. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20 (1 Pt 1): 15-20.
10. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29 (12): 1705-1713.
11. Ganne- Carrie N, Ziol M, de Ledinghen V, et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 2006; 44 (6): 1511-1517.
12. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006; 55 (3): 403-408.
13. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128 (2): 343-350.
14. Tatsumi C, Kudo M, Ueshima K, et al. Noninvasive evaluation of hepatic fibrosis using serum fibrotic markers, transient elastography (FibroScan) and real- time tissue elastography. Intervirology 2008; 51 (Suppl 1): 27-33.
15. Williams AL, Hoofnagle JH,. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988; 95 (3): 734-739.
16. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38 (2): 518-526.
17. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase- to- platelet ratio index for the staging of hepatitis C- related fibrosis: an updated meta- analysis. Hepatology 2011; 53 (3): 726-736.
18. Imbert- Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T,. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357 (9262): 1069-1075.
19. Sebastiani G, Vario A, Guido M, et al. Stepwise combination algorithms of non- invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006; 44 (4): 686-693.
20. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43 (6): 1317-1325.
21. Vallet- Pichard A, Mallet V, Nalpas B, et al. FIB- 4: An inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007; 46 (1): 32-36.
22. Vergniol J, Foucher J, Terrebonne E, et al. Noninvasive tests for fibrosis and liver stiffness predict 5- year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140 (7): 1970-1979. 1979 e1971- 1973.
23. Nunes D, Fleming C, Offner G, et al. Noninvasive markers of liver fibrosis are highly predictive of liver- related death in a cohort of HCV- infected individuals with and without HIV infection. Am J Gastroenterol 2010; 105 (6): 1346-1353.
24. Fung J, Lai CL, Seto WK, Wong DK, Yuen MF,. Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg- negative chronic hepatitis B. J Viral Hepat 2011; 18 (10): 738-744.
25. Masuzaki R, Tateishi R, Yoshida H, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 2009; 49 (6): 1954-1961.
26. Jung KS, Kim SU, Ahn SH, et al. Risk assessment of hepatitis B virus- related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 2011; 53 (3): 885-894.
27. Vergniol J, Foucher J, Castera L, et al. Changes of non- invasive markers and FibroScan values during HCV treatment. J Viral Hepat 2009; 16 (2): 132-140.
28. Mummadi RR, Petersen JR, Xiao SY, Snyder N,. Role of simple biomarkers in predicting fibrosis progression in HCV infection. World J Gastroenterol 2010; 16 (45): 5710-5715.
29. Jain MK, Seremba E, Bhore R, et al. Change in fibrosis score as a predictor of mortality among HIV- infected patients with viral hepatitis. AIDS Patient Care STDS 2012; 26 (2): 73-80.
30. Poynard T, Bedossa P,. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat 1997; 4 (3): 199-208.
31. Kurosaki M, Matsunaga K, Hirayama I, et al. The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non- response to interferon therapy. J Hepatol 2008; 48 (5): 736-742.